Accelerate Diagnostics Stock Current Valuation
| AXDX Stock | USD 1.64 0.03 1.80% |
Valuation analysis of Accelerate Diagnostics helps investors to measure Accelerate Diagnostics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to drop to -1.6 in 2024. Enterprise Value Multiple is likely to drop to -1.6 in 2024. Fundamental drivers impacting Accelerate Diagnostics' valuation include:
Enterprise Value 79.1 M | Enterprise Value Ebitda (1.10) | Price Sales 3.3575 | Enterprise Value Revenue 6.6449 |
Undervalued
Today
Please note that Accelerate Diagnostics' price fluctuation is unstable at this time. Calculation of the real value of Accelerate Diagnostics is based on 3 months time horizon. Increasing Accelerate Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Accelerate Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Accelerate Stock. However, Accelerate Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.64 | Real 3.42 | Target 9.0 | Hype 1.63 | Naive 1.43 |
The intrinsic value of Accelerate Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Accelerate Diagnostics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Accelerate Diagnostics helps investors to forecast how Accelerate stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Accelerate Diagnostics more accurately as focusing exclusively on Accelerate Diagnostics' fundamentals will not take into account other important factors: Accelerate Diagnostics Company Current Valuation Analysis
Accelerate Diagnostics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Accelerate Diagnostics Current Valuation | 79.13 M |
Most of Accelerate Diagnostics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Accelerate Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Accelerate Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Accelerate Diagnostics is extremely important. It helps to project a fair market value of Accelerate Stock properly, considering its historical fundamentals such as Current Valuation. Since Accelerate Diagnostics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Accelerate Diagnostics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Accelerate Diagnostics' interrelated accounts and indicators.
Click cells to compare fundamentals
Accelerate Current Valuation Historical Pattern
Today, most investors in Accelerate Diagnostics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Accelerate Diagnostics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Accelerate Diagnostics current valuation as a starting point in their analysis.
Accelerate Diagnostics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Accelerate Diagnostics has a Current Valuation of 79.13 M. This is 99.45% lower than that of the Life Sciences Tools & Services sector and 99.36% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.52% higher than that of the company.
Accelerate Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Accelerate Diagnostics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Accelerate Diagnostics could also be used in its relative valuation, which is a method of valuing Accelerate Diagnostics by comparing valuation metrics of similar companies.Accelerate Diagnostics is currently under evaluation in current valuation category among its peers.
Accelerate Fundamentals
| Return On Asset | -0.76 | ||||
| Operating Margin | (2.88) % | ||||
| Current Valuation | 79.13 M | ||||
| Shares Outstanding | 25.04 M | ||||
| Shares Owned By Insiders | 40.60 % | ||||
| Shares Owned By Institutions | 17.45 % | ||||
| Number Of Shares Shorted | 510.51 K | ||||
| Price To Earning | (15.18) X | ||||
| Price To Sales | 3.36 X | ||||
| Revenue | 12.06 M | ||||
| Gross Profit | 3.3 M | ||||
| EBITDA | (49.77 M) | ||||
| Net Income | (61.62 M) | ||||
| Cash And Equivalents | 36.77 M | ||||
| Cash Per Share | 0.45 X | ||||
| Total Debt | 39.22 M | ||||
| Debt To Equity | 2.76 % | ||||
| Current Ratio | 4.48 X | ||||
| Book Value Per Share | (1.36) X | ||||
| Cash Flow From Operations | (40.2 M) | ||||
| Short Ratio | 7.77 X | ||||
| Earnings Per Share | (2.59) X | ||||
| Price To Earnings To Growth | (0.55) X | ||||
| Target Price | 1.5 | ||||
| Number Of Employees | 134 | ||||
| Beta | 0.6 | ||||
| Market Capitalization | 41.07 M | ||||
| Total Asset | 31.37 M | ||||
| Retained Earnings | (668.86 M) | ||||
| Working Capital | 12.43 M | ||||
| Current Asset | 91.68 M | ||||
| Current Liabilities | 4.45 M | ||||
| Net Asset | 31.37 M |
About Accelerate Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Accelerate Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Accelerate Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Accelerate Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.